Pharmacotherapy for psychiatric inpatients with alcohol use disorder or acute intoxication: results from an observational pharmacovigilance program-status and changes between 2000 and 2016
- PMID: 40906254
- DOI: 10.1007/s00702-025-03012-z
Pharmacotherapy for psychiatric inpatients with alcohol use disorder or acute intoxication: results from an observational pharmacovigilance program-status and changes between 2000 and 2016
Abstract
Alcohol use disorder (AUD) is a mental disorder with a high prevalence and is one of the most common diagnoses requiring inpatient treatment. For the pharmacological management of withdrawal and detoxification, tranquilizing and anticonvulsant drugs, as well as symptom-triggered therapy, are recommended. In this study, we investigated the use of psychotropic drugs in the inpatient treatment of patients with AUD or acute intoxication by analyzing data from the Drug Safety Program in Psychiatry (German: Arzneimittelsicherheit in der Psychiatrie; AMSP). Patients were classified according to the ICD-10 code F10. The study included 10,332 patients treated for AUD or acute intoxication in participating hospitals between 2000 and 2016. The most frequently used drug classes were antidepressant (31.2%), antipsychotic (29.7%), anticonvulsant (26.4%) and tranquilizing drugs (24.3%), among which benzodiazepines were the most commonly used (23.6%). The most common drugs were carbamazepine (11.1%), diazepam (10.1%), mirtazapine (8.5%) and oxazepam (8.2%). Treatment patterns varied depending on sex and the presence of additional psychiatric diagnosis, such as depressive disorder. During the observation period, the use of antidepressant and antipsychotic drugs increased and the use of tranquilizing drugs doubled, while the use of clomethiazole declined. These findings underscore the need for greater attention to managing comorbidities. However, we also observed a high utilization of non-benzodiazepine sedating drugs-such as trazodone, mirtazapine and quetiapine-even though there is insufficient evidence to support their use in this context. Further research is warranted.
Keywords: AMSP; Alcohol use disorder; Antidepressant drug; Antipsychotic drug; Pharmacovigilance; Psychiatry; Psychopharmacology.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: Financial interests: ST is a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker honoraria from Janssen-Cilag, Lundbeck/Otsuka, Recordati Pharma GmbH, ROVI GmbH and Servier. JS took part in two educational events sponsored by Otsuka/Lundbeck. The research presented in this manuscript did not receive any specific grants or funding. The AMSP drug safety project is facilitated by nonprofit associations in Germany, Austria, and Switzerland. The AMSP project has been supported with unrestricted educational and research grants since 1993 by the following companies: German companies: Abbott GmbH & Co. KG, AstraZeneca GmbH, Aventis Pharma Deutschland GmbH GE–O/R/N, Bayer Vital GmbH, Boehringer Mannheim GmbH, Bristol-Myers-Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar Pharma GmbH & Co. KG, Eisai GmbH, Esparma GmbH Arzneimittel, GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung Bad Homburg, Lundbeck GmbH & Co. KG, Novartis Pharma GmbH, Nordmark Arzneimittel GmbH, Organon GmbH, Otsuka-Pharma Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta Lundbeck Arzneimittel, Recordati Pharma GmbH, Rhone-Poulenc Rohrer, Sanofi-Synthelabo GmbH, Sanofi-Aventis Deutschland, Schering AG, SmithKlineBeecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo Arzneimittel GmbH, Dr. Wilmar Schwabe GmbH & Co., Thiemann Arzneimittel GmbH, Troponwerke GmbH & Co. KG, Upjohn GmbH, Wander Pharma GmbH and Wyeth-Pharma GmbH. Austrian companies: Astra Zeneca Österreich GmbH, Boehringer Ingelheim Austria, Bristol-Myers Squibb GmbH, CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med Inform and Wyeth Lederle Pharma GmbH. Swiss companies: AHP (Schweiz) AG, AstraZeneca AG, Bristol-Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag AG, Lundbeck (Suisse) AG, Organon AG, Pfizer AG, Pharmacia, Sanofi-Aventis (Suisse) S.A., Sanofi-Synthelabo SA, Servier SA, SmithKlineBeecham AG, Solvay Pharma AG, Wyeth AHP (Suisse) AG and Wyeth Pharmaceuticals AG. BH, TG, MH, OZ, JE, RG, SB, PP, PP and MS declare no financial interest. Non-financial interests: BH, TG, MH, OZ, JE, PP, PP and MS declare no non-financial interest. SB, RG, and ST are project managers of the AMSP program. Ethical approval: The evaluated data were obtained from a completely anonymized database, ensuring that subjects could not be traced. Evaluations based on AMSP data were approved by the Ethics Committee of the University of Munich and the Ethics Committee of the Hannover Medical School (Nr. 8100_BO_S_2018).
References
-
- Andersson Sundell K, Gissler M, Petzold M, Waern M (2011) Antidepressant utilization patterns and mortality in Swedish men and women aged 20–34 years. Eur J Clin Pharmacol 67(2):169–178. https://doi.org/10.1007/s00228-010-0933-z - DOI
-
- Antonelli M, Sestito L, Tarli C, Addolorato G (2022) Perspectives on the pharmacological management of alcohol use disorder: are the approved medications effective? Eur J Intern Med 103:13–22. https://doi.org/10.1016/j.ejim.2022.05.016 - DOI - PubMed
-
- Batra A, Müller CA, Mann K, Heinz A (2016) Alcohol dependence and harmful use of alcohol: diagnosis and treatment options. Dtsch Arztebl Int. https://doi.org/10.3238/arztebl.2016.0301 - DOI - PubMed - PMC
-
- Bridler R, Häberle A, Müller ST, Cattapan K, Grohmann R, Toto S, Kasper S, Greil W (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25(6):763–772. https://doi.org/10.1016/j.euroneuro.2015.03.017 - DOI - PubMed
-
- Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, Gillis AJ, Ray LA (2022) Novel agents for the pharmacological treatment of alcohol use disorder. Drugs 82(3):251–274. https://doi.org/10.1007/s40265-021-01670-3 - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources
Miscellaneous